ANTI-PIG ANTIBODY IN INFANTS: CAN A GENETICALLY-ENGINEERED PIG HEART BRIDGE TO ALLOTRANSPLANTATION?
Congenital heart patients have high heart-transplant waitlist mortality, and mechanical support is suboptimal. To evaluate feasibility of cardiac grafts from a genetically-engineered triple-knockout pig as a bridge to allotransplantation, preformed anti-pig antibodies were measured in pediatric and adult patients. Flow cytometry measured serum IgM/IgG binding to wild-type and triple-knockout red blood cells (RBCs), with binding to human O-negative RBCs as a negative control. Group 1: 84 pediatric patients and 64 healthy adults' sera with no previous cardiac surgery. Group 2: 25 infant's sera post-cardiac surgery, including 10 after palliation for hypoplastic left heart syndrome. Group 1: IgM binding to wild-type RBCs occurred in 80% and IgG binding in 91% sera. Only 3% sera showed IgM binding to triple-knockout RBCs, and one (<1%) was weakly positive for IgG binding. Group 2: All 25 infants demonstrated increased IgM and IgG binding to wild-type RBCs. One patient showed minimal IgM and another low IgG binding to triple-knockout RBCs. No infant after stage I Norwood demonstrated any IgG or IgM binding. Preformed anti-pig antibodies may not be a barrier to heart xenotransplantation in infants, even after cardiac surgery. With adequate immunosuppressive therapy, a triple-knockout pig heart transplant might function successfully as a bridge to allotransplantation.